NCT01242579撤回1 期
A Double-Blind, Randomised, Placebo-Controlled Phase I Trial to Compare the Pharmacokinetics of Maraviroc and Dapivirine Following Application of Maraviroc Vaginal Vaginal Gel, 0.1% 2.5g, Dapivirine Vaginal Gel, 0.05%, 2.5g and Maraviroc 0.1% + Dapivirine 0.05% Vaginal Gel, 2.5g Formulations, and to Assess Their Safety as Compared to the Matching Placebo Vaginal Gel, 2.5g in Healthy, HIV-Negative Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Safety: To assess the safety and tolerability of the combination maraviroc and dapivirine gel, the endpoint was the proportion of women in the four arms experiencing specific, protocol defined safety events during the study (see description).
研究概览
简要总结
The purpose of this study is to assess the pharmacokinetics of the combination dapivirine and maraviroc gel and determine whether it is safe for daily use by healthy women in the United Kingdom
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women 18 to40 years of age who can give written informed consent (illiterate participants may provide a thumbprint or mark witnessed and signed by a person independent from trial staff);
- •Available for all visits and consent to follow all procedures scheduled for the trial;
- •HIV-negative as determined by an HIV test at time of enrollment;
- •Be on a stable form of contraception, defined as:
- •A stable oral contraceptive regimen for at least 2 months prior to enrollment, OR,
- •Transdermal contraceptive patch for at least 3 months prior to enrollment, OR,
- •Long-acting progestins for at least 6 months prior to enrollment, OR,
- •An IUD inserted (with no vaginal or gynaecological complaints associated with its use) at least 3 months prior to enrolment, OR,
- •Have undergone surgical sterilization at least 3 months prior to enrollment;
- •In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle, defined as having a minimum of 21 days and a maximum of 35 days between menses;
- •Upon pelvic examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the Investigator;
- •Asymptomatic for genital infections at the time of enrollment (if a woman is diagnosed with any treatable STI, either syndromically or by laboratory test at the time of screening, she must receive treatment at least 2 weeks prior to enrollment and have completed treatment);
- •Willing to refrain from the use of vaginal products or objects including, tampons, female condoms, cotton wool, rags, diaphragms, cervical caps (or any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying agents for 14 days prior to enrollment and for the duration of the trial;
- •Willing to use oral contraceptives to avoid menstruation, if necessary, while taking part in this trial;
- •Documentation of no abnormality on Pap test, including grossly bloody smear, within 3 months prior to screening;
- •Willing to refrain from participation in any other research trial for the duration of this trial;
- •Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures [e.g., by home visit or telephone; or via family or close neighbour contacts (confidentiality to be maintained)];
- •Willing to agree to abstain from oral contact with her genitalia for gel use period, as well as for a total of 3 days (72 hours) after the biopsy procedure:
- •Willing to remain sexually abstinent for the gel use period in this trial;
- •Hepatitis B and C negative at the time of enrollment.
排除标准
- •Currently pregnant or having had their last pregnancy outcome within 3 months prior to screening;
- •Currently breast-feeding;
- •Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening;
- •Untreated symptomatic urogenital infections, e.g., urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, within 2 weeks prior to enrolment;
- •Presence of any abnormal clinically significant physical finding on the vulva, vaginal walls or cervix during pelvic examination and/or colposcopy at pre-enrolment;
- •History of urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence;
- •Current vulvar or vaginal symptoms/abnormalities that could influence the trial results;
- •Pap test result that requires cryotherapy, biopsy, treatment (other than for infection); or further evaluation [this includes any findings of atypical squamous cells of undetermined significance (ASCUS)];
- •Symptomatic genital HSV infection or a history of genital herpetic infection;
- •Any Grade 2, 3 or 4 haematology, chemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading Adverse Events (NOTE: This table can be found at: http://rcc.tech-res.com/safetyandpharmacovigilance;and a standardized version will be provided to the research centre in the Study Operations Manual);
- •Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment;
- •Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone;
- •Any serious acute, chronic or progressive disease (e.g., any known history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV, AIDS, or blood dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition;
- •Have undergone a hysterectomy;
- •History of drug abuse within 1 year of enrollment;
- •Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.
研究组 & 干预措施
Maraviroc Vaginal Gel
Active Comparator
Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
干预措施: Maraviroc Vaginal Gel (Drug)
Dapivirine Vaginal Gel
Active Comparator
Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
干预措施: Dapivirine Vaginal Gel (Drug)
Matching Placebo Gel
Placebo Comparator
Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
干预措施: Matching Placebo Gel (Drug)
Maraviroc/Dapivirine Gel
Experimental
Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
干预措施: Maraviroc/Dapivirine Gel (Drug)
结局指标
主要结局
Safety: To assess the safety and tolerability of the combination maraviroc and dapivirine gel, the endpoint was the proportion of women in the four arms experiencing specific, protocol defined safety events during the study (see description).
时间窗: 8 weeks
* Mucosal abnormalities (as defined in the WHO/CONRAD manual) visible during naked eye examination and/or colposcopy; * Abnormal vaginal pH and/or abnormal vaginal flora during the course of the trial; * Positive diagnostic tests for trichomonas, gonorrhoea and/or chlamydia; * At least one adverse event during the 2 month trial period; * Any laboratory abnormalities on haematology, electrolytes, liver function, and renal function.
Pharmacokinetics: assessment of local and systemic pharmacokinetics of maraviroc and dapivirine in plasma, vaginal fluid and cervical tissue before, during and after 11 days.
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal RingHIV InfectionsNCT01363037International Partnership for Microbicides, Inc.48
已完成
1 期
Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative AdultsHIV InfectionsNCT03239483National Institute of Allergy and Infectious Diseases (NIAID)28
已完成
1 期
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United StatesHIV-1 InfectionsNCT00799058International Partnership for Microbicides, Inc.128
已完成
3 期
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsCytomegalovirus InfectionsNCT00411645Shire681
已完成
4 期
Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest RangersMalariaNCT02788864Oxford University Clinical Research Unit, Vietnam150